Brief: Helix Biopharma Q3 Loss Per Share C$0.02

Helix Biopharma

11/06/2019 14:54

June 11 (Reuters) - Helix Biopharma Corp  HBP.TO :
    * ANNOUNCES FISCAL THIRD QUARTER 2019 RESULTS
    * Q3 LOSS PER SHARE C$0.02
    * COMPANY'S LDOS001 CLINICAL STUDY CONTINUES TO FACE PATIENT
ENROLMENT CHALLENGES
    * HELIX BIOPHARMA - AS AT APRIL 30, 2019, CO HAD WORKING
CAPITAL
DEFICIENCY OF $2.2 MILLION, SHAREHOLDERS' DEFICIENCY OF $1.9
MILLION AND DEFICIT OF $169.4 MILLION
    * SOME OF CO'S VENDORS HAVE PLACED COMPANY ON HOLD (CASH IN
ADVANCE) AND IS IMPACTING COMPANY'S CLINICAL DEVELOPMENT PROGRAM
    * RE-ALLOCATED LIMITED RESOURCES TO IMPROVE PATIENT
ENROLLMENT IN
LDOS001 STUDY
    * HELIX BIOPHARMA - CASH RESERVES OF $938,000 AS AT APRIL
30,
CONTINUE TO BE INSUFFICIENT TO MEET SOME ANTICIPATED CASH NEEDS
THROUGH NEXT 12 MONTHS

Source text for Eikon:  ID:nGNXbbYWMP 
Further company coverage:  HBP.TO 

 ((Reuters.Briefs@thomsonreuters.com;))